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Lanreotide Autogel is a new long-acting aqueous preparation
of lanreotide for the treatment of acromegaly and is admin-
istered by deep sc injection from a small volume, prefilled
syringe. The aim of this study was to evaluate the efficacy and
safety of this new long-acting formulation in a large popula-
tion of acromegalic patients previously responsive to lan-
reotide 30 mg, im (sustained release microparticle formula-
tion). Lanreotide Autogel was administered by deep sc
injection every 28 d to 107 patients (54 males and 53 females;
mean age, 54  1.2 yr). All patients had been treated with
lanreotide (30 mg) for at least 3 months before study entry and
had a mean GH level less than 10 ng/ml after at least 4 sub-
sequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%).
Treatment was switched from lanreotide 30 mg injected every
14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respec-
tively, every 28 d. After three fixed dose injections of lan-
reotide Autogel, mean lanreotide levels were similar to those
obtained at steady state with lanreotide 30 mg. During lan-
reotide Autogel treatment, the control of acromegalic symp-
toms was comparable with that previously achieved during
lanreotide 30 mg treatment. After 3 injections of lanreotide
Autogel, mean GH (2.870.22 ng/ml) and IGF-I (31715 ng/ml)
values were comparable with those recorded at the end of
lanreotide 30 mg treatment (GH, 2.82 0.19 ng/ml; IGF-I, 323
16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized
IGF-I were achieved in 33% and 39% of patients during lan-
reotide 30 mg and lanreotide Autogel treatment, respectively.
Diarrhea, abdominal pain, and nausea were reported by 38%,
22%, and 18% of patients during lanreotide 30 mg treatment
and by 29%, 17%, and 9% of patients, respectively, during lan-
reotide Autogel treatment. In conclusion, this clinical study
shows that lanreotide Autogel is at least as efficacious and
well tolerated as lanreotide 30 mg. This new long-acting lan-
reotide formulation, lanreotide Autogel, which is adminis-
tered from a small volume, prefilled syringe by deep sc injec-
tion, is therefore likely to improve the acceptability of medical
treatment for patients requiring long-term somatostatin an-
alog therapy. (J Clin Endocrinol Metab 87: 99–104, 2002)
TREATMENT WITH somatostatin analogs, such as lan-reotide and octreotide, is the first-line medical therapy
for acromegaly (1–3). The suppressive effects of these analogs
on somatotroph activity are reversible and do not persist
for long after drug withdrawal. Long-acting release forms
of somatostatin analogs, such as lanreotide 30 mg and
octreotide-LAR, avoid the drawback of daily sc injections or
continuous infusion using a pump. These depot formulations
have been produced by the incorporation of lanreotide or
octreotide in microparticles of biodegradable polymer and
are injected im every 7–28 d. In short-term (4–6) and long-
term (7, 8) clinical studies, lanreotide 30 mg achieves a con-
trol of GH hypersecretion similar to that previously obtained
with daily sc injections or continuous infusion of octreotide.
However, long-term treatment of acromegaly with fewer
injections should further improve patient acceptability of this
therapy.
Lanreotide Autogel is a new delivery formulation (man-
ufactured by Beaufour-Ipsen Group, Paris, France), which is
available in a small volume, prefilled syringe and is admin-
istered by deep sc injection. The aim of this study was to
evaluate the efficacy and safety of this new long-acting lan-
reotide preparation in acromegalic patients previously re-
sponsive to lanreotide 30 mg.
Subjects and Methods
Patients
A total of 144 acromegalic patients (69 males and 75 females), aged
53  1 yr (mean  sem), were included in this open comparative
multicenter study (Intend to Treat population), after having been as-
sessed for the safety analysis. Hypertension, diabetes mellitus, and im-
paired glucose tolerance were present in 38%, 26%, and 12% of the
patients, respectively. Thirty-five percent of them had received hor-
monal replacement therapy for partial or complete hypopituitarism.
Before somatostatin analog therapy, the mean IGF-I level was 646  27
ng/ml. During lanreotide 30 mg administration, 11 patients withdrew
due to adverse events unrelated to lanreotide or to protocol deviations
(pancreatic neoplasm, n 1; lung cancer, n 1; protocol deviation, n
3; mean GH 10 ng/ml at the end of treatment, n  6). A total of 26
patients also withdrew during lanreotide Autogel administration due toAbbreviations: CI, Confidence interval.
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adverse events (hot flushes, mild nausea, and tenesmus, n  1) and
protocol deviation (n  25). Overall, 107 patients (54 males and 53
females; mean age, 54 1.2 yr) completed the study in accordance with
the protocol (i.e. Per Protocol population).
The mean time since diagnosis of acromegaly was 11 0.8 yr (mean
sem). A total of 83 patients had undergone pituitary surgery, and 49 had
received external radiotherapy at least 6 months and 1 yr, respectively,
before the study. These patients had a diagnosis of active acromegaly
(basal mean GH level5 ng/ml, elevated age-normalized IGF-I, or GH
level2 ng/ml after an oral glucose tolerance test) after surgery and/or
radiotherapy and within 5 yr before the study. The mean residual tumor
size was 16  1 mm (n  60). All patients had been treated with im
injections of lanreotide 30 mg for at least 3 months before study entry
and were considered to be responsive to the somatostatin analog lan-
reotide because they had a mean plasma GH level less than 10 ng/ml
during lanreotide 30 mg administration. None of the patients received
either a dopamine agonist or another somatostatin analog treatment
during the study. All patients gave written informed consent, and the
study was approved by the institutional ethics committee of each study
center.
Study protocol
During the first part of the study, lanreotide 30 mg was administered
every 14, 10, or 7 d to 48%, 32%, or 20% of the patients, respectively. Each
patient received five im injections. When the next injection was due,
patients were injected with lanreotide Autogel administered via a pre-
filled syringe. Patients received 60, 90, or 120 mg by deep sc injection
every 28 d instead of lanreotide 30 mg by im injection every 14, 10, or
7 d, respectively. Three 28-d fixed dose injections were administered.
Immediately before im or deep sc injection and after overnight fasting,
blood was taken every 30 min for 4 h to provide nine measurements of
GH concentration. Plasma IGF-I and lanreotide levels were also deter-
mined immediately before lanreotide 30 mg and lanreotide Autogel
injections.
To evaluate the clinical efficacy of lanreotide, patients were asked to
grade each of their symptoms (headache, night sweats, asthenia, swell-
ing of extremities, and joint pain) as absent, mild, moderate, or severe
at the end of each treatment period. To assess adverse events, gastro-
intestinal symptoms (diarrhea, abdominal pain, nausea, constipation,
and vomiting) and symptoms local to the injection site (pain, itching,
induration, and redness) were documented at each visit before and 30
min after each lanreotide injection.
Blood samples for hematology and biochemistry analyses were taken,
and gallbladder echography was performed at the end of lanreotide 30
mg and lanreotide Autogel treatments.
Hormone assays
The plasma GH concentration was measured using an immunora-
diometric assay from Nichols Institute Diagnostics (San Juan Capistrano,
CA), with a detection limit of 0.02 ng/ml and intra- and interassay
coefficients of variation of less than 4.2% and 7.2%, respectively. After
an ethanol-acid extraction, a plasma IGF-I assay was performed by
means of the IGF-I immunoradiometric assay kit from Nichols Institute
Diagnostics. The detection limit of this assay was 6 ng/ml, and the intra-
and interassay coefficients of variation were less than 3.3% and 10.3%,
respectively. The concentration of lanreotide was analyzed by an RIA
method with a detection limit of 0.08 ng/ml, and intra- and interassay
coefficients of variation of less than 5% and 13%, respectively. All hor-
mone and lanreotide assays were centralized.
Data analysis
A sample size of 100 patients in the Per Protocol population provides
a power of greater than 80% to demonstrate the noninferiority of lan-
reotide Autogel. This noninferiority study was designed to show that
lanreotide Autogel was not less effective than lanreotide 30 mg in con-
trolling acromegaly as measured by mean GH levels. GH and IGF-I
levels were analyzed using ANOVA, and lanreotide Autogel was con-
sidered noninferior to lanreotide 30 mg if the upper limit of the 95%
confidence interval (CI) did not exceed 1.25. This approach is similar to
that recommended to test noninferiority of pharmacokinetic parameters.
The primary population was the Per Protocol one; however, to show the
robustness of the results, the analysis was also performed on the Intend
to Treat population. Subgroup analyses were also performed according
to the dose of lanreotide Autogel received (60, 90, and 120 mg). De-
scriptive statistics for lanreotide serum levels were presented for main
time points.
Results
Efficacy of lanreotide Autogel injections
The mean plasma GH level was 2.82 0.19 ng/ml (mean
sem) 7–14 d after the last lanreotide 30 mg injection, and this
increased to 3.51 0.28 ng/ml at d 28 after the first injection
of lanreotide Autogel when the serum lanreotide concentra-
tion was at the nadir, confirming that patients had active
GH-secreting pituitary tumors. After the three lanreotide
Autogel injections, the mean GH value decreased to 2.87 
0.22 ng/ml and was comparable with the value recorded at
the end of lanreotide 30 mg treatment (upper 95% CI, 1.041;
this value is lower than the 1.25 limit, demonstrating that
lanreotide Autogel is no less effective than lanreotide 30 mg;
Fig. 1A and Table 1). The results in the Intend to Treat
population show a similar trend (upper 95% CI, 1.078). The
changes in the GH value were similar for each dose group of
patients, and mean GH levels were lower in the 60 mg group
(2.33  0.25 ng/ml) and higher in the 120 mg group (3.92 
0.48 ng/ml) than in the 90 mg group (3.03 0.45 ng/ml) after
the three lanreotide Autogel injections.
The mean plasma IGF-I value measured during lanreotide
30 mg treatment (323  16 ng/ml) also confirmed noninfe-
riority after one (345  16 ng/ml) or three (317  15 ng/ml)
injections of lanreotide Autogel (upper 95% CI, 1.034 in the
Per Protocol population, and 1.022 in the Intend to Treat
population; Fig. 1B).
During lanreotide 30 mg treatment, mean GH levels less
than 2.5 ng/ml and serum age-normalized IGF-I values were
present in 51 (48%) and 48 (45%) patients, respectively. After
the 3 lanreotide Autogel injections, the number of patients
with GH levels less than 2.5 ng/ml and the number of pa-
tients with age-normalized IGF-I values were 60 (56%) and
51 (48%), respectively. The numbers of patients with both GH
below 2.5 ng/ml and age-normalized IGF-I levels were 35
(33%) and 42 (39%) at the end of lanreotide 30 mg and
lanreotide Autogel treatments, respectively.
During lanreotide 30 mg treatment, most patients reported
acromegalic symptoms that were mild or moderate in se-
verity. The control of clinical symptoms of acromegaly dur-
ing lanreotide Autogel treatment was comparable with that
previously achieved during lanreotide 30 mg injections. The
most common symptom was joint pain, reported by 39% of
patients during lanreotide 30 mg treatment and by 38% of
patients during lanreotide Autogel treatment (Table 2).
Changes in lanreotide levels during lanreotide 30 mg and
lanreotide Autogel injections
During lanreotide 30 mg treatment, the mean lanreotide
level, measured 7–14 d after im injections, was greater than
1 ng/ml and did not show any relevant change (i.e. steady
state) during the last five injections of lanreotide 30 mg (Fig.
2). At the end of lanreotide 30 mg treatment, mean lanreotide
levels were higher in patients treated with one injection every
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7 d (3.10  0.25 ng/ml) or 10 d (2.65  0.20 ng/ml) than in
those injected every 14 d (1.86 0.12 ng/ml). After lanreotide
30 mg withdrawal, the mean lanreotide levels, measured 28 d
after the first deep sc injection of lanreotide Autogel, had
decreased in each dose group. The mean lanreotide levels
measured 28 d after each subsequent deep sc injection of
lanreotide Autogel increased in each group. After three lan-
reotide Autogel injections, the mean lanreotide levels were
not different from the values obtained at steady state with
FIG. 1. Mean levels (SEM) of GH (A), IGF-I (B), and lanreotide (C) in 107 acromegalic patients treated with im lanreotide 30 mg and deep
sc lanreotide Autogel injections.
TABLE 1. Plasma GH and IGF-I (mean  SEM) in acromegalic
patients during im lanreotide (30 mg) treatment and after one and




1st injection Last injection
GH (ng/ml) 2.82  0.19 3.51  0.28 2.87  0.22
IGF-I (ng/ml) 323  16 345  16 317  15
TABLE 2. Percentage of acromegalic symptoms in patients







Night sweats 23 21
Asthenia 32 29
Swelling of extremities 34 28
Joint pain 39 38
Percentages are shown.
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lanreotide 30 mg injections (lanreotide 30 mg, 2.37  0.11
ng/ml; lanreotide Autogel, 2.17  0.09 ng/ml; Fig. 1C).
Tolerability of lanreotide Autogel injections
Minor gastrointestinal problems, such as diarrhea, abdom-
inal pain, and nausea lasting less than 72 h, were reported
during the study (Table 3). After treatment with lanreotide
30 mg and lanreotide Autogel, diarrhea was reported by 38%
and 29% of patients, abdominal pain by 22% and 17% of
patients, and nausea by 18% and 9% of patients, respectively.
In most patients, these adverse events were mild to moder-
ate. Mild pain, itching, and induration at the site of injection
occurred in less than 7% of patients during lanreotide 30 mg
or lanreotide Autogel treatment. The prevalence of either
gallstones or sludge was 38% for patients receiving lan-
reotide 30 mg and 41% for patients receiving lanreotide Au-
togel. Finally, during lanreotide Autogel treatment there was
no evidence of significant change in the routine hematolog-
ical and biochemical parameters evaluated during the study
compared with those at the end of treatment with lanreotide
30 mg.
Discussion
The effectiveness of somatostatin analog treatment in ac-
romegalic patients has been found to correlate with the mo-
lecular characteristics of the somatotroph cells (9–15) as well
as with the plasma concentration of somatostatin analog (3,
13). In clinical studies, control of GH hypersecretion in ac-
romegalic patients responsive to somatostatin analogs has
been improved by increasing the dose of sc octreotide (14) or
the frequency of im lanreotide 30 mg injections (4–6).
Control of GH hypersecretion during treatment with oc-
treotide LAR or lanreotide 30 mg has been reported to be
similar to that obtained during sc octreotide treatment (6, 9,
15–18). In this current study of acromegalic patients treated
with lanreotide 30 mg injections every 7–14 d, the mean GH
level was less than 2.5 ng/ml in 48% of patients, and there
was an age-/sex-normalized IGF-I in 45% of patients. During
lanreotide Autogel treatment, the mean GH level was less
than 2.5 ng/ml, and IGF-I levels were normalized in 56% and
47% of patients, respectively. During lanreotide 30 mg and
lanreotide Autogel treatments, GH hypersecretion was con-
trolled with the mean GH level less than 2.5 ng/ml and an
age-sex-normalized IGF-I value (19) in 33% and 39% of pa-
tients, respectively. Therefore, this clinical study shows that
in patients with GH-secreting pituitary adenomas, deep sc
injections of lanreotide Autogel every 28 d are at least as
efficacious as im injections of lanreotide 30 mg every 7–14 d
in controlling GH hypersecretion.
The mean lanreotide level measured 7–14 d after the last
injection of lanreotide 30 mg was significantly higher in the
90 and 120 mg groups than in the 60 mg group. Therefore,
differences in lanreotide levels between patients responsive
to lanreotide 30 mg suggest that patients in the 60 mg group
are more sensitive to lanreotide than those in the 90 and 120
mg groups. Such variable sensitivities of acromegalic pa-
tients to somatostatin analogs have been found to correlate
with the number, distribution, and activity of somatostatin
receptor subtypes on the GH-secreting adenoma (9–11) and
the adenylate cyclase activity in somatotroph cells (12).
After long-term lanreotide 30 mg treatment, mean lan-
reotide levels decrease following withdrawal of lanreotide 30
mg and are less than 1 ng/ml 28 d after the last injection (20).
However, the decrease in lanreotide levels is different be-
tween groups treated with lanreotide 30 mg every 10 and
14 d, suggesting that the clearance rate of lanreotide may
vary in acromegalic patients. This in conjunction with the
variable sensitivities described above may explain the vari-
able doses of lanreotide Autogel required to control GH
hypersecretion in acromegalic patients.
On the basis of pharmacokinetic studies, the administered
doses of lanreotide Autogel were determined according to
the dosing interval of lanreotide 30 mg. During lanreotide
Autogel treatment, plasma lanreotide levels (measured 28 d
after each injection) progressively increased in all groups.
However, the steady state for the lanreotide level was not
obtained after the first three injections of lanreotide Autogel
due to the long half-life of the drug (25–30 d). This pattern
FIG. 2. Mean lanreotide level (SEM) in acromegalic patients treated
with im lanreotide 30 mg injections (group 1, every 14 d; group 2, every
10 d; group 3, every 7 d) and 28-d lanreotide Autogel injections (group
1, 60 mg; group 2, 90 mg; group 3, 120 mg).
TABLE 3. Percentage of gastrointestinal symptoms, local signs at
sites of injection, and abnormal gall-bladder echographies in
acromegalic patients treated with im lanreotide (30 mg) and deep
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suggests that there is a cumulative effect during the first
injections of lanreotide Autogel, as previously shown in ac-
romegalic patients treated with either sc octreotide (21) or im
lanreotide 30 mg injections (22). After three deep sc injections
of lanreotide Autogel, mean lanreotide levels were signifi-
cantly different in the 60 mg group and the 90 or 120 mg
groups and were similar to the values obtained at steady state
with lanreotide 30 mg. Furthermore, during short-term treat-
ment with lanreotide Autogel (administered every month for
3 months), plasma lanreotide levels were higher than 1 ng/
ml, enabling lanreotide Autogel to reduce plasma GH and
IGF-I concentrations in acromegalic patients responsive to
lanreotide 30 mg (22).
Somatostatin analog treatment is well tolerated in most
patients. The main side-effects reported by patients are mi-
nor gastrointestinal problems, such as diarrhea, abdominal
pain, and nausea. In most patients, gastrointestinal side-
effects become less frequent during long-term treatment and
do not lead to interruption of treatment. In this current study
gastrointestinal side-effects reported during lanreotide 30
mg treatment are comparable with those reported in previ-
ous studies (4, 5, 7, 8, 22). After the first injection of lanreotide
Autogel, there are fewer reported gastrointestinal adverse
events (diarrhea, abdominal pain, and nausea) than during
long-term lanreotide 30 mg administration. The relatively
high frequency of gastrointestinal symptoms reported after
im lanreotide 30 mg injections may be explained by the
pharmacokinetic profile of the formulation. Lanreotide 30
mg is composed of microparticles containing lanreotide.
Plasma lanreotide levels reach a peak 2 h after im injection
due to the rapid release of the analog localized at the surface
of the copolymer and then decline over 48 h. Subsequently,
they increase and then progressively decrease until d 10–14
following injection. Conversely, lanreotide Autogel is an
aqueous preparation of lanreotide acetate administered by
deep sc injection. Lanreotide levels increase, but the peak
lanreotide level is lower than it is with lanreotide 30 mg, and
it subsequently decreases over a 28-d period. This might
explain why the frequency of gastrointestinal problems re-
ported during lanreotide Autogel treatment seems to be
lower than that reported at the beginning of lanreotide 30 mg
treatment. During lanreotide 30 mg and lanreotide Autogel
treatments, mild and transient pain at the injection site with
local itching or induration occur with similar frequency
(7%). The most potentially important adverse event during
long-term somatostatin analog administration is an in-
creased tendency for gallstone formation. In this study gall-
bladder echography performed after three lanreotide Auto-
gel injections did not reveal any significant increase in the
presence of gallstones or sludge. Thus, a similar percentage
of patients reported mild or moderate side-effects during
lanreotide 30 mg and lanreotide Autogel treatments. These
results show that lanreotide Autogel is as well tolerated as
lanreotide 30 mg in acromegalic patients.
In conclusion, this clinical study shows that when given at
the same monthly dose, lanreotide Autogel is at least as
efficacious and well tolerated as lanreotide 30 mg in patients
with a GH-secreting pituitary adenoma. This new long-
acting lanreotide formulation is administered by deep sc
injection every 28 d from a small volume, prefilled syringe
and is likely to improve the acceptability of medical treat-
ment for acromegalic patients who need long-term soma-
tostatin analog therapy.
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